Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof

US12331129B2 · kind B2 · utility

Assignees

• Memorial Sloan Kettering Cancer Center · US
• Sloan Kettering Institute for Cancer Research · US
• MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES · US
• Millennium Pharmaceuticals, Inc. · US

Inventors

• Michel Sadelain · New York, US
• Sascha P. Haubner · New York, US
• Jorge Mansilla-Soto · Queens, US
• Xingyue He · Cambridge, US
• Gary Shapiro · Arlington, US

Key dates

• Filing date: Apr 25, 2022
• Grant date: Jun 17, 2025
• Expiry date: May 30, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.